Pharmaceuticals Brazil

Brazil Multiple Sclerosis Drugs Market Analysis, 2024–2034

Brazil Multiple Sclerosis Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Brazil · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $608.0 Mn Estimated value
Estimate 2025 $627.4 Mn 2.3% of the global market
Projected 2034 $833.0 Mn 32.8% Adds $205.6 Mn over 9 forecast years
CAGR 2025–2034 3.2% Faster than 1% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Brazil is 2.3% of the global market.
  • In Latin America, the largest is Brazil (this report) at $627.4 Mn.
  • Fastest growing: Brazil (this report) at 3.2% a year.
  • Brazil ranks 1st of 3 by size in Latin America.

Market size projection

Brazil

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$205.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Multiple Sclerosis Drugs Market market size by year, Brazil
YearMarket sizeChange that yearSince 2025
2024 (estimate) $608.0 Mn — —
2025 (base) $627.4 Mn +$19.5 Mn —
2026 (forecast) $647.5 Mn +$20.1 Mn +3.2%
2027 (forecast) $668.2 Mn +$20.7 Mn +6.5%
2028 (forecast) $689.6 Mn +$21.4 Mn +9.9%
2029 (forecast) $711.7 Mn +$22.1 Mn +13.4%
2030 (forecast) $734.4 Mn +$22.8 Mn +17.1%
2031 (forecast) $757.9 Mn +$23.5 Mn +20.8%
2032 (forecast) $782.2 Mn +$24.3 Mn +24.7%
2033 (forecast) $807.2 Mn +$25.0 Mn +28.7%
2034 (forecast) $833.0 Mn +$25.8 Mn +32.8%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $27.32 Bn
  2. North America $13.58 Bn
  3. US $12.33 Bn
  4. Europe $5.60 Bn
  5. APAC $5.04 Bn
  6. China $2.57 Bn
  7. Canada $2.43 Bn
  8. Japan $1.55 Bn
  9. Latin America $1.35 Bn
  10. Middle East $1.22 Bn
  11. Germany $1.05 Bn
  12. UK $755.0 Mn
  13. France $739.5 Mn
  14. Italy $703.0 Mn
  15. Brazil (this report) $627.4 Mn
  16. Ecuador $555.8 Mn
  17. India $583.3 Mn
  18. Spain $468.3 Mn
  19. Mexico $475.3 Mn
  20. Saudi Arabia $447.7 Mn
  21. Africa $390.8 Mn
  22. Russia $303.3 Mn
  23. Australia $313.0 Mn
  24. New Zealand $259.2 Mn
  25. South Africa $163.4 Mn
  26. UAE $142.7 Mn
  27. Egypt $77.1 Mn
  28. Philippines $67.2 Mn
  29. Malaysia $42.1 Mn
  30. Hong Kong $39.6 Mn
  31. Thailand $37.9 Mn
  32. Singapore $31.4 Mn
  33. Kenya $19.6 Mn

The Brazil Multiple Sclerosis Drugs Market Analysis Executive Summary

Multiple sclerosis drugs reduce relapses and slow disability in this immune disease of the brain and spinal cord.

Key segments of the multiple Sclerosis Drugs market include drug class (Anti-CD20 Antibodies, S1P Modulators and Interferons) and route (Infusion, Injectable and Oral).

Brazil Multiple Sclerosis Drugs Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the multiple Sclerosis Drugs market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the multiple Sclerosis Drugs market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the multiple Sclerosis Drugs market.

Competitive Landscape for Multiple Sclerosis Drugs Market in Brazil

The multiple Sclerosis Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Multiple Sclerosis Drugs Market in Brazil

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for multiple Sclerosis Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Brazil.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Multiple Sclerosis Drugs right now, from free public sources.

Clinical trials

24 active trials in Brazil

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Novartis AG 29 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Roche 24 active trials on ClinicalTrials.gov (opens in a new tab)
  3. TG Therapeutics 9 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Bristol-Myers Squibb 7 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Sanofi 7 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 15 papers since 2021 (worldwide)

  1. Use of multiple sclerosis drugs among pregnant individuals with live-birth deliveries in the FDA's Sentinel Distributed Database. BMC pregnancy and childbirth, 2026
  2. Industry payments to US neurologists related to multiple sclerosis drugs and prescribing (2015-2019): a retrospective cohort study. BMJ open, 2025
  3. Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs. Journal of managed care & specialty pharmacy, 2024
  4. How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased? American economic journal. Economic policy, 2024
  5. A DFT study on the probability of using the heteroatom decorated graphitic carbonitride (g-C(3)N(4)) species for delivering of three novel Multiple sclerosis drugs. Journal of molecular graphics & modelling, 2023
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Multiple Sclerosis Drugs in context

Brazil compared

  • Health spending per person: 1,010 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 4 countries we cover in Latin America.[1]
  • Doctors: 2.36 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 4 countries we cover in Latin America.[2]
  • People aged 65 and over: 11.5% of people (2025). World: 10.4% of people (2025). Highest of the 4 countries we cover in Latin America.[3]

Questions, answered with public data

How many clinical trials on Multiple Sclerosis Drugs are running in Brazil?
24 studies are recruiting, active or about to start in Brazil.[4]
How much research is published on Multiple Sclerosis Drugs?
PubMed lists 15 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Multiple Sclerosis Drugs in Brazil? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Alzheimer's Diagnosis: Blood Tests and Earlier Answers57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help… Cannabis-Based Medicines: Science and RegulationThe FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Brazil

See all
Same topic, other categories

Related on autoimmune diseases and brain and nerves

See the topic